In the present study, we observed that the combination of melatonin and doxorubicin reduced the level of AMPKα1, which acts as a critical survival factor for cancer cells; this phenomenon was seen in many different cancer cells, including breast cancer cells, and was also evident in cells subjected to combined treatment with melatonin and other cancer drugs. This evidence concerns the gene PRKAA1 and cancer.